| DB ID | MyCo_5416 |
| Title | An investigation into biomarkers for the diagnosis of ABPA and aspergillus disease in cystic fibrosis |
| Year | 2019 |
| PMID | 31359612 |
| Fungal Diseases involved | Allergic bronchopulmonary aspergillosis |
| Associated Medical Condition | Cystic fibrosis |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | This study was approved by the Children’s and Women’s Research Ethics Board (H13‐00676) and informed consent was obtained. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | FENO (37.8 ppb) |
| Biomarker Full Name | Exhaled nitric oxide (37.8 ppb) |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Canada |
| Cohort | We performed a prospective observational cohort study in a tertiary pediatric CF center in Vancouver, British Columbia between December 2012 and May 2014. A total of 62 patients were included in the study: 13% ABPA, 19% AFS, and 68% non‐AFS. |
| Cohort No. | 62 |
| Age Group | None |
| P Value | p=.04 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease due to Aspergillus fumigatus (Af). It occurs in approximately 10% of patients with cystic fibrosis (CF) and is associated with accelerated lung function decline, more frequent hospitalizations, and greater CF morbidity. Making a diagnosis of ABPA is particularly challenging in patients with CF as clinical features are often indistinguishable from bacterial pulmonary exacerbation and laboratory criteria may reflect sensitization and not disease. This can lead to overdiagnosis of ABPA with subsequent side effects of systemic steroids or underdiagnosis and lack of treatment leading to clinical deterioration. |
| Technique | Assay |
| Analysis Method | NIOX MINO assay |
| ELISA kits | enzyme‐linked immuno- sorbent assay Kit (ImmunoCAP ECP), NIOX MINO Kit (Aerocrine, Sweden) |
| Assay Data | None |
| Validation Techniques used | NIOX MINO assay |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
